Abstract
Introduction: The incidence of type 1 diabetes (T1D) is increasing worldwide and there is a very large need for effective therapies. Essentially no therapies other than insulin are currently approved for the treatment of T1D. Drugs already in use for type 2 diabetes and many new drugs are under clinical development for T1D, including compounds with both established and new mechanisms of action.
Content of the Review: Most of the new compounds in clinical development are currently in Phase 1 and 2. Drug classes discussed in this review include new insulins, SGLT inhibitors, GLP-1 agonists, immunomodulatory drugs including autoantigens and anti-cytokines, agents that regenerate β-cells and others. Regulatory Considerations: In addition, considerations are provided with regard to the regulatory environment for the clinical development of drugs for T1D, with a focus on the United States Food and Drug Administration and the European Medicines Agency. Future opportunities, such as combination treatments of immunomodulatory and beta-cell regenerating therapies, are also discussed.Keywords: Type 1 diabetes, new drug development, regulatory environment, FDA, EMA, new mechanisms of action, insulins; anti-inflammatory drugs, immunomodulatory, islet regeneration.
Current Diabetes Reviews
Title:Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Volume: 13 Issue: 3
Author(s): Friedrich Mittermayer*, Erica Caveney, Claudia De Oliveira, G. Alexander Fleming, Loukas Gourgiotis, Mala Puri, Li-Jung Tai and J. Rick Turner
Affiliation:
- Quintiles GmbH, Stella-Klein-Löw Weg 15, Rund 4, Haus B, OG 4, 1020 Vienna,Austria
Keywords: Type 1 diabetes, new drug development, regulatory environment, FDA, EMA, new mechanisms of action, insulins; anti-inflammatory drugs, immunomodulatory, islet regeneration.
Abstract: Introduction: The incidence of type 1 diabetes (T1D) is increasing worldwide and there is a very large need for effective therapies. Essentially no therapies other than insulin are currently approved for the treatment of T1D. Drugs already in use for type 2 diabetes and many new drugs are under clinical development for T1D, including compounds with both established and new mechanisms of action.
Content of the Review: Most of the new compounds in clinical development are currently in Phase 1 and 2. Drug classes discussed in this review include new insulins, SGLT inhibitors, GLP-1 agonists, immunomodulatory drugs including autoantigens and anti-cytokines, agents that regenerate β-cells and others. Regulatory Considerations: In addition, considerations are provided with regard to the regulatory environment for the clinical development of drugs for T1D, with a focus on the United States Food and Drug Administration and the European Medicines Agency. Future opportunities, such as combination treatments of immunomodulatory and beta-cell regenerating therapies, are also discussed.Export Options
About this article
Cite this article as:
Mittermayer Friedrich*, Caveney Erica, De Oliveira Claudia, Fleming Alexander G., Gourgiotis Loukas, Puri Mala, Tai Li-Jung and Turner Rick J., Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development, Current Diabetes Reviews 2017; 13 (3) . https://dx.doi.org/10.2174/1573399812666160413115655
DOI https://dx.doi.org/10.2174/1573399812666160413115655 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro Studies
Current Drug Targets Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Current Medicinal Chemistry Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) GHB in Biological Specimens: Which Cut-off Levels Should be Taken into Consideration in Forensic Toxicological Investigation?
Recent Patents on Biotechnology Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry The Central Nervous System as a Promising Target to Treat Diabetes Mellitus
Current Topics in Medicinal Chemistry Role of Ischemia Modified Albumin Serum Levels as an Oxidative Stress Marker in Children with Diabetic Ketoacidosis
Combinatorial Chemistry & High Throughput Screening Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes
Current Bioactive Compounds Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry An Overview of Valuable Scientific Models for Diabetes Mellitus
Current Diabetes Reviews Risk Factors for Suicide – An Alternative View
CNS & Neurological Disorders - Drug Targets SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature
Current Clinical Pharmacology Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Antimicrobial Action of Chelating Agents: Repercussions on the Microorganism Development, Virulence and Pathogenesis
Current Medicinal Chemistry Hyperglycemic Hyperosmolar State: A Pragmatic Approach to Properly Manage Sodium Derangements
Current Diabetes Reviews